AEGR Share Price

Open 1.89 Change Price %
High 2.34 1 Day 0.10 5.35
Low 1.86 1 Week 0.00 0.00
Close 1.97 1 Month 0.17 9.44
Volume 2166128 1 Year -7.78 -79.79
52 Week High 10.85
52 Week Low 0.00
AEGR Important Levels
Resistance 2 2.41
Resistance 1 2.23
Pivot 2.06
Support 1 1.71
Support 2 1.53
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR)

AEGR Technical Analysis 4
As on 29th Nov 2016 AEGR Share Price closed @ 1.97 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.26 & Sell for SHORT-TERM with Stoploss of 2.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
AEGR Target for December
1st Target up-side 2.43
2nd Target up-side 2.75
3rd Target up-side 3.07
1st Target down-side 1.51
2nd Target down-side 1.19
3rd Target down-side 0.87
AEGR Other Details
Segment EQ
Market Capital 560309632.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aegerion.com
AEGR Address
AEGR
101 Main Street
Suite 1850
Cambridge, MA 02142
United States
Phone: 617-500-7867
Fax: 617-945-7968
Interactive Technical Analysis Chart Aegerion Pharmaceuticals, Inc. ( AEGR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Aegerion Pharmaceuticals, Inc.
AEGR Business Profile
Aegerion Pharmaceuticals, Inc. (Aegerio), incorporated in February 2005, is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH. The Company’s lead product compound, lomitapide, is a small molecule microsomal triglyceride transfer protein (MTP), inhibitor (MTP-I), that the Company developed as an oral once-a-day treatment for patients with certain severe lipid disorders in 2011. Lomitapide has been evaluated in 14 Phase I and eight Phase II clinical trials, as well as the Phase III clinical trial completed in 2011. Approximately 940 patients have been treated with lomitapide as part of these clinical trials. As of December 31, 2011, it developed lomitapide as an oral, once-a-day treatment for patients with HoFH and familial chylomicronemia (FC).